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Recently reporting in Nature, Barber et al. demonstrated that SIRT7 maintains critical features that define
cancer cells by removing the acetylation mark on lysine 18 of histone H3. Interestingly, hypoacetylation of
H3K18 has been described as a general marker of tumor prognosis and oncoviral transformation.Sirtuins are NAD+-dependent deacety-
lases that target histone and non-histone
proteins and are major factors in the
response to oxidative, metabolic, and
genotoxic stresses. Their responses are
global and occur at many different levels;
consequently, Sirtuins are at the cross-
roads among the foremost pathways
that control cellular fate, including those
for survival, genomic stability, apoptosis,
and energy or metabolic adaptation. The
importance of Sirtuins is reflected by
their implication in several major human
pathologies, including cancer, diabetes,
cardiovascular diseases and neurode-
generative diseases (Bosch-Presegue´
and Vaquero, 2011).
Mammals have seven Sirtuins (denoted
SIRT1–7) that have considerably different
functions and catalytic activities. SIRT7
has been one of the most puzzling
Sirtuins. Although researchers had clearly
identified SIRT7 in chromatin, they had
not found any clear catalytic activity or
target specificity for it. The only target
that had been proposed for SIRT7 was
p53, but this is currently under debate.
Evidence has supported a crucial rolefor SIRT7 in oxidative and genotoxic
stress response. Homozygous knockout
of Sirt7 in mice causes diminished life-
span and leads to heart hypertrophy
and inflammatory cardiopathy. Cardio-
myocytes derived from these mice show
increased apoptosis as well as hyper-
sensitivity to oxidative and genotoxic
stress. However, other than an ill-defined
functional relationship between SIRT7
and p53 activity, no clear molecular ex-
planation has been determined for these
phenomena (Vakhrusheva et al., 2008b).
Another reported role for SIRT7 is in
the control of ribosomal RNA (rRNA)
expression. SIRT7 localizes mainly in the
nucleolus, where it binds to the rRNA
genes (rDNA) and participates in activa-
tion of RNA-polymerase I (pol-I) transcrip-
tion (Figure 1A). Although this function
apparently depends on SIRT7 having an
intact ‘‘catalytic domain’’ (defined by
homology to other Sirtuins), no mecha-
nism has been described (Ford et al.,
2006). However, some evidence suggests
that this SIRT7 function may be specific
to certain cell types (Vakhrusheva et al.,
2008b; Barber et al., 2012). Interestingly,SIRT7 is relevant for the reactivation of
rDNA transcription at the end of mitosis.
Although the exact mechanism of SIRT7
action here is unknown, its interactions
with the poI-I cofactors UBF and chro-
matin remodeling complex B-WICH have
been described (Grob et al., 2009). Based
on these findings and that SIRT7 is more
abundant in highly proliferative tissues
than in lowly proliferative tissues, a role
for SIRT7 as a principal activator of prolif-
eration has been proposed. On the
contrary, other findings have suggested
that SIRT7 may inhibit proliferation (Ford
et al., 2006; Vakhrusheva et al., 2008a).
This discrepancy has been a subject of
controversy until now.
A recent report in Nature by Barber
et al. (2012) represents a major break-
through in SIRT7 research and redefines
our view on the role of Sirtuins in cancer.
The authors discovered a specific target
of SIRT7 and identified a crucial role for
SIRT7 in the maintenance of cancer
phenotype and transformation. They
found that SIRT7 is specific for a single
histone mark, acetylated lysine 18 in
histone H3 (H3K18Ac), directly linked to21, June 12, 2012 ª2012 Elsevier Inc. 719
Figure 1. SIRT7 Modulates Protein Biosynthesis and Maintains Tumor Phenotype through
H3K18Ac Deacetylation
(A) SIRT7 is involved in the transcription of rDNA by RNA-polymerase I (pol-I) through its catalytical activity
of an undescribed substrate. For this function, SIRT7 has been shown to interact with the pol-I cofactor
UBF and the UBF-binding chromatin remodeling complex B-WICH.
(B) SIRT7 represses the transcription of 241 genes, many of which are involved in protein synthesis,
through deacetylation of H3K18Ac in these promoters.
(C) SIRT7 is responsible for tumor phenotype maintenance and proliferation through deacetylation of
H3K18Ac. Depletion of SIRT7 inhibits tumor growth in vivo.
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H3K18Ac is mainly present in a sharp
peak around the transcription start site
of genes and has been linked to activa-
tion of nuclear hormone receptors
(Wang et al., 2008). Moreover, H3K18
hypoacetylation has been reported as
a marker of malignancy in various human
cancers (Seligson et al., 2009) and has
been linked to the ability of the adeno-
virus small early region 1a (e1a) protein
to trigger oncogenic transformation (Fer-
rari et al., 2008; Horwitz et al., 2008).720 Cancer Cell 21, June 12, 2012 ª2012 ElsBarber et al. (2012) performed ChIP
sequencing experiments and identified
276 binding sites for SIRT7 in the
genome, corresponding to 241 protein-
coding genes. In 74% of these genes,
SIRT7 was mainly present in the pro-
moter proximal regions where it directly
regulated the H3K18Ac level. Among
the most represented genes regulated
by SIRT7 through H3K18 deacetylation
were those involved in different stages
of regulation of protein biosynthesis,
including RNA processing and proteinevier Inc.translation (Figure 1B). Interestingly,
the expression of many of these genes
is deregulated in various cancers. A limi-
tation of this study is that binding of
SIRT7 to rDNA sites was not determined
in this approach, as repetitive DNA
sequences are not easily processed in
ChIP-seq analysis. Sequence analysis
of SIRT7-occupied promoters led to
identification of ELK4, a MAPK-signaling
dependent ETS transcription factor,
as a partner of SIRT7. Almost 60% of
the SIRT7-binding sites contain ELK4-
binding motifs, and ELK4 depletion
decreases the binding of SIRT7 at these
promoters.
How this repressive regulatory func-
tion of SIRT7 in protein biosynthesis
reconciles with a proactive role in
rDNA transcription activation should be
determined in the future; the mechanism
involved in rDNA transcription is likely
distinct to that of H3K18Ac deacetylation.
Whether both events occur simulta-
neously or under different physiological
conditions (e.g., stress or tumorigenesis)
also remains to be addressed.
The ChIP-seq results of Barber et al.
(2012) and the previously known link
between H3K18Ac and cancer together
corroborate an important role for SIRT7
in tumorigenesis. Consistent with this
premise, SIRT7 has been reported to be
upregulated in breast and thyroid
cancers (Bosch-Presegue´ and Vaquero,
2011). Based on these findings, Barber
et al. (2012) show that SIRT7 enzymatic
activity is responsible for maintaining
some of the most important features
of human cancer cells, such as
anchorage-independent growth, growth
in low serum, and loss of contact inhi-
bition. Importantly, depletion of SIRT7
inhibited the growth of human cancer
cells as tumor xenografts in mice
(Figure 1C). Interestingly, SIRT7 is also
required for transformation by e1a and
is responsible for the H3K18 hypoacety-
lation observed upon transformation.
Given the limited number of SIRT7-regu-
lated genes, it is possible that a small
pool of genes is involved in the pro-
tumorigenic function of SIRT7. In the
case of e1a transformation, SIRT7 may
undergo specific relocalization. Future
studies should be able to clarify this
issue and identify these genes.
The work of Barber et al. (2012)
is a significant advance toward
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in cancer, a rather complicated subject.
To date, Sirtuins have only been linked
to cancer as collateral factors, rather
than as direct effectors. They may help
modulate various pathways that could
favor or disfavor tumor development ac-
cording to physiological context. Inter-
estingly, SIRT7 is not actively involved
in establishing cancer phenotype, but it
is fundamental for maintaining this
phenotype (Barber et al., 2012). Thus, it
would be interesting to determine
whether Sirt7 knockout mice are more
resistant to tumorigenesis. Whether this
function stems from a specific role of
SIRT7 in promoting tumor proliferation
or is related to the functions of other
Sirtuins, remains an open question. The
relationship of this SIRT7 function to
stress response and the context of this
relationship are also unknown. The
answer probably lies in the control of
protein biosynthesis, as metabolic andenergetic stress induce blockage of ribo-
some production and alterations in these
processes are linked to tumorigenesis
and aging.
In the light of the report by Barber
et al. (2012), we speculate that develop-
ment of specific modulators of SIRT7
may be crucial for helping control tumor
progression or even for reversing cancer
phenotype. Answering these questions
should prove to be an exciting challenge
in the future. Regardless, this work has
made it clear that when it comes to
cancer, Sirtuins are here to stay.REFERENCES
Barber, M.F., Michishita-Kioi, E., Xi, Y., Tasselli,
L., Kioi, M., Moqtaderi, Z., Tennen, R.I., Paredes,
S., Young, N.L., Chen, K., et al. (2012). Nature.
Published online May 6, 2012. 10.1038/
nature11043.
Bosch-Presegue´, L., and Vaquero, A. (2011).
Genes Cancer 2, 648–662.Cancer CellFerrari, R., Pellegrini, M., Horwitz, G.A., Xie, W.,
Berk, A.J., and Kurdistani, S.K. (2008). Science
321, 1086–1088.
Ford, E., Voit, R., Liszt, G., Magin, C., Grummt, I.,
and Guarente, L. (2006). Genes Dev. 20, 1075–
1080.
Grob, A., Roussel, P., Wright, J.E., McStay, B.,
Hernandez-Verdun, D., and Sirri, V. (2009). J. Cell
Sci. 122, 489–498.
Horwitz, G.A., Zhang, K., McBrian, M.A., Grun-
stein, M., Kurdistani, S.K., and Berk, A.J. (2008).
Science 321, 1084–1085.
Seligson, D.B., Horvath, S., McBrian, M.A., Mah,
V., Yu, H., Tze, S., Wang, Q., Chia, D., Goodglick,
L., and Kurdistani, S.K. (2009). Am. J. Pathol.
174, 1619–1628.
Vakhrusheva, O., Braeuer, D., Liu, Z., Braun, T.,
and Bober, E. (2008a). J. Physiol. Pharmacol. 59,
201–212.
Vakhrusheva, O., Smolka, C., Gajawada, P.,
Kostin, S., Boettger, T., Kubin, T., Braun, T., and
Bober, E. (2008b). Circ. Res. 102, 703–710.
Wang, Z., Zang, C., Rosenfeld, J.A., Schones,
D.E., Barski, A., Cuddapah, S., Cui, K., Roh, T.Y.,
Peng, W., Zhang, M.Q., and Zhao, K. (2008). Nat.
Genet. 40, 897–903.21, June 12, 2012 ª2012 Elsevier Inc. 721
